LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of “Buy” by Analysts

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has earned an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $35.40.

Separately, TD Cowen assumed coverage on shares of LENZ Therapeutics in a research report on Tuesday. They set a “buy” rating and a $60.00 target price for the company.

Hedge Funds Weigh In On LENZ Therapeutics

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of LENZ Therapeutics by 5.3% in the 4th quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock worth $34,022,000 after purchasing an additional 59,630 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in LENZ Therapeutics by 83.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock valued at $23,760,000 after acquiring an additional 374,326 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new position in LENZ Therapeutics during the 4th quarter valued at $22,243,000. State Street Corp lifted its stake in LENZ Therapeutics by 18.7% during the 3rd quarter. State Street Corp now owns 289,154 shares of the company’s stock valued at $6,865,000 after acquiring an additional 45,600 shares in the last quarter. Finally, Alyeska Investment Group L.P. lifted its stake in LENZ Therapeutics by 16.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company’s stock valued at $4,103,000 after acquiring an additional 20,000 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Stock Down 7.3 %

LENZ Therapeutics stock opened at $23.59 on Tuesday. The business has a 50 day moving average of $24.16 and a 200-day moving average of $27.02. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.